title: HLA-DR2 predicts a favorable response to cyclosporine therapy in patients with bone marrow failure.
authors.forename: S
authors.initials: S
authors.lastname: Nakao
authors.forename: M
authors.initials: M
authors.lastname: Yamaguchi
authors.forename: M
authors.initials: M
authors.lastname: Saito
authors.forename: S
authors.initials: S
authors.lastname: Yasue
authors.forename: S
authors.initials: S
authors.lastname: Shiobara
authors.forename: T
authors.initials: T
authors.lastname: Matsuda
authors.forename: M
authors.initials: M
authors.lastname: Nitta
authors.forename: M
authors.initials: M
authors.lastname: Sasaki
mesh_terms: D001855:Bone Marrow Diseases / Q000188:drug therapy* / Q000276:immunology*; D016572:Cyclosporine / Q000627:therapeutic use*; D015802:HLA-DR2 Antigen / Q000032:analysis*
chemical_list: D015802:HLA-DR2 Antigen; D016572:Cyclosporine